Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Abzena technology used to enhance Faron Pharma's cancer drug

The company used its Composite Human Antibody platform to enhance the drug
clinical trial graphic
The work was carried out in the US with support from the company's UK operation

Abzena PLC (LON:ABZA) has successfully manufactured a potential new cancer drug that incorporates the company’s Composite Human Antibody platform.

The ‘Abzena Inside’ technology was deployed to enhance Clevegen, a pre-clinical treatment being developed by Faron Pharmaceuticals Ltd (LON:FARN).

READ: Abzena signs manufacturing and bioconjugational agreement with Telix​

Abzena said the manufacture of the new product took place at its site in San Diego, but used the bioanalytics and bioassay expertise of its Cambridge operation.

"We are pleased to have enabled the progression of an Abzena Inside antibody towards clinical development through this partnership,” said Jim Mills, head of technical operations.

“It really demonstrates the depth of our integrated services and technologies, showing how our sites work together to provide the support that our partners require to move their products forward from molecule design into clinical trials."

The company has a twin strategy: it provides support services for the bio-pharma industry and it grafts its technologies into drugs hoping to enhance efficacy.

The latter is the company’s ‘Abzena Inside’ strategy, which mirrors the approach taken by chipmaker Intel, which provides the processors that power millions of PCs and laptops worldwide.

View full ABZA profile View Profile

Abzena PLC Timeline

Related Articles

nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand
July 02 2018
The research and diagnostic company develops cancer-detecting blood tests
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use